Abstract The most common apolipoprotein E (APOE) allelic variation is implicated in many age-related diseases and human longevity with controversial findings. We investigated the effect of APOE gene polymorphism on all-cause mortality in elderly patients taking into consideration the functional disability, cognitive impairment, malnutrition, and the occurrence of common age-related diseases. APOE genotypes were determined in 2,124 geriatric hospitalized patients (46.5% men and 53.5% women; mean age, 78.2± 7.1 years; range, 65-100 years). At hospital admission, all patients underwent a comprehensive geriatric assessment to evaluate functional disability, cognitive status, nutritional status, and comorbidity. The main and secondary diagnoses at hospital discharge were also recorded. Mortality status was evaluated in all patients after a maximum follow-up of 5 years (range, from 1.26 to 5.23 years; median, 2.86 years). During the study period, 671 patients died (32.0%). At hospital admission, these patients showed a significant higher prevalence of cardiovascular diseases (56.3% vs 53.4%; p= 0.007), neoplasias (32.3% vs 13.7%; p<0.001), and lower prevalence of neurodegenerative diseases (17.7% vs 20.7%; p<0.001) than survived patients. Moreover, they also showed an higher prevalence of disability (52.0% vs 25.6%; p<0.001), cognitive impairment (31.0% vs 18.8%; p<0.001), and malnutrition (74.0% vs 46.1%; p<0.001) than survived patients. In the overall study population, the APOE ε2 allele was significantly associated to neurodegenerative diseases (odds ratio=0.59; 95% confidence interval (CI), 0.37-0.94). No significant association between the APOE polymorphism and disability, malnutrition, comorbidity status, and with all-cause mortality was observed. In patients with cardiovascular diseases, however, a decreased risk of all-cause mortality was found in the ε2 allele carriers (hazard ratio=0.56; 95% CI, 0.36-0.88). In this population, APOE allele variants might play a role on cardiovascular diseaserelated mortality.
Introduction
Previous studies on heritability of human longevity showed that genetic factors may account, approximately, for 20-30% of the overall variation in adult lifespan (Herskind et al. 1996; Iachine et al. 1998; De Benedictis et al. 2001; Hjelmborg et al. 2006) . The genetic influence on lifespan appears to be greater at extreme aging (Perls et al. 1998) , and individuals living to extreme old age are healthy and independent for most of their lives (Hitt et al. 1999) . Although longevity might show Mendelian inheritance, aging and the susceptibility to age-related diseases may be influenced by environment, lifestyle, and probably by thousands of genes (Perls et al. 2002) .
The exact identity of aging and longevity genes is unknown. In the quest to understand the biologic basis of human longevity, it can be supposed that genes and biochemical markers likely implied in coronary artery disease, cerebrovascular disease, and Alzheimer's disease (AD) may have a role in human longevity (Panza et al. 2007 ). The apolipoprotein E (APOE) gene polymorphism is one of the most studied gene variation in the world; its most common allelic variations of APOE gene (ε2, ε3, and ε4) have been associated with many common age-related diseases. In fact, the APOE gene has been widely examined in different studies, because of its welldocumented role in dementia as well as vascular diseases. It has been identified as a genetic risk factor for cognitive decline and AD (Hsiung et al. 2004; Mahley et al. 2006 ) and cardiovascular diseases (Song et al. 2004; Licastro et al. 2004) , and it has been shown as a risk modulator of many other disorders (Jofre-Monseny et al. 2008) . Notably, a relevant number of reports on human longevity showed APOE ε4 allele frequency being lower in older age groups (centenarians, octogenarians, and nonagenarians) than younger or middle-aged subjects (Lewis and Brunner 2004) . The ε2 allele conversely has a higher frequency in younger than older population (Panza et al. 2007) , and it has been suggested to decrease the risk for major age-related diseases, including AD, while its role in the cardiovascular diseases is not clear (Song et al. 2004 ).
At present, the effect of APOE polymorphism on mortality in the general population is not clear, and several studies reported conflicting results (Corder et al. 1996; Koivisto et al. 2000; Frisoni et al. 2001; Slooter et al. 2001; Hayden et al. 2005) . Moreover, differences in the association between this polymorphism and mortality have been reported across European (Ewbank 2004 ) and other populations (Ewbank 2007) . Aim of the present study was to explore the potential association of APOE alleles on all-cause mortality in a large population of Caucasian hospitalized elderly patients from Central and Southern Italy, taking also into account the functional disability, cognitive impairment, malnutrition, and the occurrence of common age-related diseases.
Methods

Study population
The study was conducted according to the Declaration of Helsinki and the guidelines for Good Clinical Practice and was approved by the local Ethics Committees. Patients were recruited from the Geriatric Unit of our Institution, in a frame of a project investigating the incidence of genetic risk factors for multidimensional impairment of elderly in Italy. All subjects were Caucasian and originating from Central and Southern Italy. Inclusion criteria were (1) age ≥65 years, (2) written informed consent obtained from the patient or from relatives of critically ill patients, and (3) availability of genetic data.
From January 2004 to December 2007, 2,792 patients, consecutively admitted to the Geriatric Unit of the IRCCS "Casa Sollievo della Sofferenza," San Giovanni Rotondo, Italy, were screened for eligibility. From this population, 233 patients were excluded because they were younger than 65 years old, 52 patients did not give their informed consent, and 383 patients were excluded because information about their mortality/survival status was not available. Vital status up to March 31, 2009 was assessed by directly contacting the participants or consulting the Registry Offices of the cities where the patients were residents at the time of hospital admission. Dates of death were identified from death certificates.
Comprehensive geriatric assessment and clinical diagnoses At baseline, the following parameters were collected by structured interview, clinical evaluation, and review of records from the patients' general practitioners: date of birth, gender, clinical history, current pathologies, and medication history. Data on demographic variables and medical history were obtained from patients or their caregivers at the baseline interview.
A comprehensive geriatric assessment (National Institutes of Health Consensus Development Conference Statement 2003) was carried out to determine the patient's functional and cognitive capacity, comorbidity, nutritional status, drug use, and social problems. Functional status was evaluated using the activities of daily living (ADL) index (Katz et al. 1970) , which defines the level of dependence/independence of six daily personal care activities, including bathing, toileting, feeding, dressing, urine and bowel continence, and transferring in and out of bed or chair (score 0-6). Cognitive status was evaluated using the short portable mental status questionnaire (SPMSQ) (Pfeiffer 1975 ), a ten-item questionnaire evaluating orientation, memory, attention, calculation, and language (score 0-10). The nutritional status was evaluated by means of the mini nutritional assessment (MNA; Guigoz and Vellas 1999) , which includes information regarding anthropometric measures (body mass index, body weight/height 2 , mid-arm circumference in centimeters, calf circumference in centimeters, and weight loss), lifestyle, medication, and mobility, number of meals, food, and fluid intake, and autonomy of feeding and self-perception of health and nutrition. A 30-point scoring system was proposed for the MNA, with an MNA score ≥24 points identifying a normal nutrition status, an MNA score of 17-23.5 points that suggested a borderline status/at risk for malnutrition, and an MNA score ≤17 points identifying malnutrition (Guigoz and Vellas 1999) . Comorbidity was evaluated by the cumulative illness rating scale (CIRS) (Linn et al. 1968) . It uses fivepoint ordinal scales (score 1-5) to estimate the severity of pathology in each of 13 systems, including cardiac, vascular, respiratory, eye-ear-nose-throat, upper and lower gastroenteric diseases, hepatic, renal, genitourinal, musculoskeletal, skin disorders, nervous system, and endocrine metabolic and psychiatric behavioral problems. Based on the ratings, the comorbidity index (CI) reflects the number of concomitant diseases, and it is derived from the total number of categories in which moderate or severe levels (grades from 3 to 5) of disease are quoted (range from 0 to 13). A CIRS-CI score of 0 indicated no concomitant diseases, a CIRS-CI score from 1 to 2 indicated one or two concomitant diseases, and a CIRS-CI score ≥3 indicated more than three concomitant diseases. The main and secondary diagnoses at discharge from the hospital, coded according to the Italian translation of the International Classification of Diseases, ninth revision, Clinical Modification (ICD-9-CM; available at URL: http://icd9cm.chrisendres. com/icd9cm/), were also recorded in all patients. In particular, cardiovascular diseases included the following diseases classified as ICD-9-CM code: 401-405, 410-414, and 415-429; neoplasia included diseases classified as ICD-9-CM code 140-239; and neurodegenerative diseases included diseases classified as ICD-9-CM code: 330-337.
Genotype analysis Genomic DNA was manually purified from peripheral blood by organic protein extraction and ethanol precipitation according to standard method. The APOE genotypes were determined by polymerase chain reaction (PCR) and agarose gel electrophoresis as recently described (Seripa et al. 2006a ). Briefly, a combination of four specific primers in three different pairs sharing the same stringent PCR conditions was used. Allelespecific primers were ASP1 (CGG ACA TGG AGG ACG TGT), ASP2 (CGG ACA TGG AGG ACG TGC), ASP3 (CTG GTA CAC TGC CAG GCG), and ASP4 (CTG GTA CAC TGC CAG GCA), synthesized by Invitrogen (Invitrogen Corporation, Carlsbad, CA, USA). The primer pair ASP-1/ASP-4 identifies the ε2 allele, the primer pair ASP-1/ASP-3 identifies the ε3 allele, and the primer pair ASP-2/ ASP-3 identifies the ε4 allele. On an Applied Biosystems GeneAmp PCR System 9700, the amplification conditions were 94°C for 2 min, followed by 32 cycles at 96°C for 15 s, 61°C for 30 s, and 72°C for 30 s. Reaction buffer included 1.5 U of Taq DNA polymerase (Platinum Taq, Invitrogen Corporation, Carlsbad, CA, USA), 10 pmol of each primer, 100 μM NTPs, and 1 mM MgCl 2 . The presence/ absence of specific allele PCR products detected by electrophoresis analysis on a 2% agarose gel identified the six APOE genotypes.
Statistical analysis Normal distribution of continuous variables was checked using the KolmogorovSmirnov test. Comparisons across groups were evaluated using unpaired t test or one-way analysis of variance model for continuous variables and Pearson's chi-square test for categorical variables.
In the analysis of the APOE polymorphism, we considered allele carriers according to the three common human APOE: ε2, ε3, and ε4 alleles. The ε3/ε3 genotype was the reference category. ε2-and ε4 carriers were considered subjects with those genotypes showing at least one APOE allele, i.e., subjects with the ε2/ε2 or ε2/ε3 genotypes (ε2 carriers) and subjects with ε3/ε4 or ε4/ε4 genotypes (ε4 carriers). Carriers of ε2/ε4 genotypes were excluded from the analysis.
Variables were dichotomized as follows: subjects with an ADL score=6 were classified as subjects with no functional disability, and subjects with ADL score ≤6 were classified as subjects with functional disability; subjects with SPMSQ score ≥3 were classified as subject with cognitive impairment, and those with the score ≤3 were classified as subject without cognitive impairment; subjects with an MNA score ≥24 had a satisfactory nutritional status, while score ≤24 identified subject with non-satisfactory nutritional status (at risk for malnutrition status and malnutrition status were pooled); and subjects with CIRS=0 were classified as having no co-morbidity with respect to subjects with CIRS ≥0. Associations between diseases and impairment in physical, cognitive, and nutritional status across APOE carriers at baseline were estimated using univariate logistic regression models. Results were reported as odds ratios (OR) along their 95% confidence interval (CI). Multivariate logistic models were built using a stepwise variable selection with p value for entry and stay in the model ≤0.20 and adjusting for age and gender.
Survival time was calculated in years from entry into the study until the time of death or the end of follow-up. Differences in survival probabilities were analyzed by comparing Kaplan-Meier survival curves using the log rank test. Furthermore, a multivariate Cox model was estimated using a stepwise variable selection, as above described, to identify which demographic or clinical variables contribute significantly to the model fit. Risks were reported as hazard ratios (HR) along their 95% CI. In all the analyses, the level of statistical significance was set at a p value ≤0.05. Agreement of the observed genotype frequencies with the expected Hardy-Weinberg frequencies were verified with Arlequin Software (Schneider et al. 2000; Kocsis et al. 2004 ). All other statistical analyses were made with the SPSS Ver. 10.1.3 statistical software package (SPSS Inc., Chicago, IL, USA).
Results
The complete data of APOE genotyping were available for 2,124 subjects selected for the study. The overall frequencies of the APOE genotypes were 10.4% for the ε2/ε3 genotype (n=220), 1.2% for the ε2/ε4 genotype (n=25), 72.1% for the ε3/ε3 genotype (n=1,531), 15.6% for the ε3/ε4 genotype (n=331), 0.7% for the ε4/ε4 genotype (n=15), and 0.1% for the ε2/ε2 genotype (n=2). These frequencies were not different from the expected Hardy-Weinberg frequencies (p=0.16). Estimated allele frequencies were 0.059 for the ε2 allele, 0.850 for the ε3 allele, and 0.091 for the ε4 allele.
After APOE genotyping, 25 patients with ε2/ε4 genotype were excluded from the analyses; thus, a total of 2,099 unrelated subjects (977 men and 1,122 women; mean age, 78.21±7.11 years; range, from 65 to 100 years) were selected for the study. At baseline, women were significantly older (78.7±7.2 vs 77.7± 7.0 years, p=0.002) and showed a major impairment in physical disability (ADL, 36.8% vs 30.8%; p= s0.004), cognitive functions (SPMSQ, 26.2% vs 18.5%; p ≤ 0.001), and nutritional status (MNA, 60.6% vs 48.1%; p≤0.001) than men. Conversely, men showed a significant higher frequency of neoplasia than women (25.1% vs 15.0%; p≤0.001).
Dividing patients by their APOE genotype (Table 1) , no significant differences in mean age, gender, and in the prevalence of cardiovascular diseases, neoplasias, physical disability, comorbidity, and malnutrition status were observed in ε2 and ε4 carriers with respect to ε3/ε3 subjects. In the multivariate analysis, a significant association between ε2 carriers and neurodegenerative diseases (OR = 0.59; 95% CI, 0.37-0.94; p=0.03) was observed (Table 2) .
At the end of follow-up (range, from 1.3 to 5.2 years; median, 2.9 years), 671 patients died (32.0%; 352 men and 319 women; mean age, 81.70± 7.58 years; Table 3 ). The prevalence of mortality was associated with male gender (men 52.5% vs women 47.5%; HR=1.46; 95% CI, 1.22-1.75; p<0.001), cardiovascular diseases (HR=1.31; 95% CI, 1.08-1.58; p=0.01), and neoplasias (HR=2.43; 95% CI, 1.99-2.97; p<0.001), while the mortality risk was lower in elderly with neurodegenerative diseases (HR=0.65; 95% CI, 0.50-0.83; p=0.001). Frequency of APOE polymorphism did not differ between dead and alive (Table 3) . Differences between KaplanMeier survival curves according to APOE genotype (ε3/ε3, ε2, and ε4 carriers) were not statically significant (log rank test, p=0.11).
In the Cox regression analysis, after adjustment for age, gender, concomitant diseases, functional and cognitive impairment, and nutritional status, no APOE allele was associated with all-cause mortality. Table 4 shows the results of the multivariate analysis performed on population stratified according to diseases, adjusted for age, gender, co-morbidity, malnutrition, and functional and cognitive impairment. In patients with cardiovascular diseases, carriers of the APOE ε2 allele had a significantly lower risk of mortality than the subjects with the APOE ε3/ε3 genotype (HR=0.56; 95% CI, 0.36-0.88). There were no other significant differences in the risk of all-cause mortality between APOE ε2 and ε4 carriers with respect to ε3/ε3 subjects among several stratification groups.
Discussion
In the present study, we examined the effect of APOE polymorphism on all-cause mortality in elderly hospitalized patients. The study was carried out in a relatively large series of geriatric patients recruited from the Geriatric Unit of our Institution, all Caucasians originating from Central and Southern Italy. No significant association between the APOE ε4 allele and all-cause mortality was found. Conversely, a protective effect on all-cause mortality of the APOE ε2 allele was evident in patients with cardiovascular diseases.
The effect of APOE polymorphism on mortality or human longevity has been studied extensively, but it remains a matter of debate (Panza et al. 2009 ). Most of the association studies on APOE polymorphism in centenarians have, up to now, used the cross-sectional design, and this kind of study is susceptible to secular changes in population genetic parameters, cohort effect, and population stratification (Panza et al. 2007 ). Nonetheless, several reports have provided longitudinal data concerning APOE and mortality, with inconsistent findings (Frisoni et al. 2001; Ewbank 2002; Hayden et al. 2005 ; Panza et al. 2007). Furthermore, the cohort studies carried out to date, which have looked at APOE and longevity also not in centenarian populations, tend to have short follow-up periods (typically 5 years) Bathum et al. 2006 ); hence, they only provide a snapshot of overall survival. Finally, although the cohort study design is expensive because of long-term follow-up, cohort studies on the oldest-old subjects can be reasonably carried out given the high mortality rate at advanced ages, and association studies using a follow-up design on nonagenarians and centenarians have already been conducted (Panza et al. 2007; Louhija et al. 2001; Bathum et al. 2006) , not confirming the role of APOE polymorphism suggested in cross-sectional reports. Although several studies reported the adverse effect of ε4 allele on survival in older people (Tilvis et al. 1998; Hayden et al. 2005) and in a wide variety of ethnic groups (Ewbank 2007) , and significant associations of the ε4 allele with mortality dependently of AD (Dal Forno et al. 2002; Rosvall et al. 2009 ) or cognitive impairment (Rockwood et al. 2008 ) have been shown, other studies reported controversial results on the relationship between this allele and longevity (Gerdes et al. 1992) , or with the risk of vascular or nonvascular mortality (Panza et al. 2007 ). Indeed, the lack of association between the ε4 allele and increased risk of mortality reported in the present study is consistent with several other reports (Skoog et al. 1998; Koivisto et al. 2000; Frisoni et al. 2001; Slooter et al. 2001; Tschanz et al. 2004 ). This finding might support the hypothesis that the importance of the APOE ε4 allele as a risk factor for mortality decreases with age (Olichney et al. 1997; Panza et al. 2007 ). In fact, in a population of centenarians identified from the Finnish National Population Register in 1991, no CVD cardiovascular disease, NDD neurodegenerative disease, ADL activities of daily living, SPMSQ short portable mental status questionnaire, CIRS-CI cumulative illness rating scale-comorbidity index, MNA mini nutritional assessment a Age-and gender-adjusted significant survival differences at a 3-year follow-up among different APOE allele carriers was found, suggesting that in this very selected group, the protection/risk effect associated with the APOE polymorphism might be attenuated . Similar results were obtained in a recent 5-year followup study of 1,551 Danish nonagenarians and in a cohort of 63 Spanish nonagenarians (Bathum et al. 2006; Formiga et al. 2006) . Moreover, taking into consideration that the mortality risk associated with ε4 allele is modest in Europeans (Ewbank 2007) , and that a decreasing trend for the ε4 allele from Northern to Southern regions of Europe in persons older than 65 years and centenarians was reported (Panza et al. 1999; Ewbank 2004) , the low frequency of this allele in our population from Southern Italy could explain the lack of association between this allele and mortality. Beyond the suggested negative effect of the ε4 allele on survival and human longevity, there is a growing evidence of a protective effect of the ε2 allele (Kulminski et al. 2008) . In fact, in the present study, in patients with cardiovascular disease, this allele appeared to be protective on all-cause mortality. The ε2 allele has been reported to reduce the risk for common geriatric diseases (Martin 1999; Eichner et al. 2002 ) (e.g., AD and cardiovascular disease) and related mortality in Caucasian elderly people (Lee et al. 2001) . Moreover, an association of the APOE ε2 allele with aging and longevity has been also confirmed in a recent cross-sectional study of Caucasian subjects from Southern Italy, where a significant higher prevalence of ε2 allele was found in subjects 60-90 years old and in centenarians compared to younger groups (Seripa et al. 2006b ). The beneficial effect of this allele was confirmed by the findings from the Kungsholmen Project, a population-based study on 1,094 individuals aged >75 years followed for 18 years, where a 28% decreased mortality risk was observed for those subjects with the ε2 allele (Rosvall et al. 2009) , although this protective effect was not found by other studies (Koivisto et al. 2000; Slooter et al. 2001; Fillenbaum et al. 2003) . At present, it seems that significant differences in APOE-related mortality may be suggested, but the different study design and follow-up periods of these population-based studies may explain the different results (Panza et al. 2009 ). Moreover, in general, the effect of one gene is dependent on a host of factors misleading study results (i.e., genetic background, age, gender, and physiological and pathological conditions). In fact, the role of APOE on cardiovascular diseases and related mortality might be independent of lipid levels and not be mediated by low density lipoprotein or high density lipoprotein cholesterol or triglycerides per se (Mooijaart et al. 2006 ). In addition, cholesterol levels decline with age (Weverling-Rijnsburger et al. 1997; Abbott et al. 1998) . Other findings indicate that APOE may play additional roles in the development of coronary artery disease (CAD) through macrophage cholesterol efflux, platelet aggregation, and allele-specific antioxidant and immune activities (Davignon et al. 1999; Moghadasian et al. 2001; Stannard et al. 2001) . It has been speculated that the protective effect of the ε2 allele may be due to its hypocholesterolemic effect, but the evidence is limited (Panza et al. 2007 ). In fact, other researchers have found associations between ε2 and CAD, and between ε2 and hypertriglyceridemia (Panza et al. 2007) . Moreover, in the Cache County study, although the sample of homozygous ε2 was relatively small, significantly greater risks for early mortality were shown in persons with the ε2/ε2 genotype (Hayden et al. 2005) . Nonetheless, an association of the APOE ε2 allele with aging may be explained by two hypotheses. First, the progressively increased frequency of the ε2 allele with aging may have been a consequence of the disappearance in selected healthy participants of the ε4 allele, which is reported to be linked to a higher risk of age-related diseases and mortality (Ewbank 2002) . Indeed, APOE ε4 has been defined as a frailty allele (Panza et al. 2007) , and very recently, it has been associated with severe multidimensional impairment in hospitalized older patients ). The second hypothesis suggests that APOE ε2 could be a longevity-enhancing allele, functioning independently from other APOE alleles. This hypothesis is supported by findings showing that the frequency of ε3 did not change with advancing age, as would be expected if the ε2 increase was caused by ε4 disappearance in the oldest age group (Seripa et al. 2006b ). Indeed, an unchanged ε3 allele frequency across age has been reported to be an important prerequisite in carrying out genetic association studies on aging (Lewis and Brunner 2004) . Although in the present report the protective role of the ε2 allele was evident only in hospitalized elderly with cardiovascular diseases, we have not able to confirm the adverse effect of the ε4 allele and the protective effect of the ε2 allele for all-cause mortality in overall hospitalized elderly. However, the lack of association between APOE polymorphism and high mortality risk may be explained by a limited samplesize and a small length of follow-up. Moreover, our study was performed on a population of elderly inpatients rather than on a general older population. In this population, neoplasias were the main determinants of mortality, particularly in the women, whereas the neurodegenerative diseases had a controversial protective effect because dementia is considered a strong predictor of mortality in the elderly (Guehne et al. 2005) , also regardless of APOE genotype (Little et al. 2009 ). Although, a study reported that dementia developing in very old age is not necessarily associated with decreased life expectancy (Franzoni et al. 1996) , in our study population, the low mortality risk for this condition could be due to the short time of the follow-up. Further studies are needed to clarify the role of APOE variants on mortality in elderly patients independently of age-related diseases.
